Johnson & Johnson (JNJ) Stock: A High-Value Dividend Stock

Spread the love

JNJ is involved in healthcare research and development, manufacturing, and sales, with a primary focus on human health and well-being. JNJ stock (NYSE:JNJ) is among the best performers in the market.

JNJ Stock Valuation

The four-year average dividend yield for JNJ is 2.60%, and the current dividend yield is 2.73%. Dividends have grown at a CAGR of 5.8% over the last three years and 5.9% over the last five. The corporation has paid dividends for 59 years in a row.

On August 24, 2022, the FDA approved IMBRUVICA(R) (ibrutinib) for the treatment of pediatric patients with chronic graft-versus-host disease (cGVHD). IMBRUVICA became the first FDA-approved therapy for patients suffering from a life-threatening illness due to this approval.

The FDA approval of IMBRUVICA adds another weapon to their arsenal and has the potential to truly make a difference for those faced with this challenging disease, said Susan Stewart, Executive Director of BMT InfoNet.

JNJs net sales increased 3% year on year to $24.02 billion in the fiscal second quarter (ended June 30, 2022). Its gross profit increased by 2.4% yearly to $16.10 billion. Non-GAAP net earnings increased 4.3% from last year to $6.91 billion, while adjusted EPS increased 4.4% to $2.59.

Analysts predict that JNJs revenue will rise marginally year on year to $23.58 billion in the fiscal third quarter (ending September 30, 2022). Its earnings per share (EPS) are expected to rise 6.7% to $2.27 in the fiscal year ending December 31, 2022. In each of the previous four quarters, the company outperformed the consensus EPS estimate.

JNJ stock (NYSE:JNJ) has increased marginally over the last nine months, closing the most recent trading session at $165.39.

JNJs POWR Ratings reflect its strong fundamentals. In our proprietary rating system, the stock has an overall rating of A, which translates to a Strong Buy. The POWR Ratings are calculated by considering 118 different factors, each of which is weighted to an optimal degree.

It received an A in Stability and a B in Growth, Value, and Quality. JNJ stock (NYSE:JNJ) is ranked first in the Medical Pharmaceuticals industry out of 167 stocks.

Featured Image – Megapixl (C) Alexeynovikov

Please See Disclaimer

Visit To Get More Articles Like This

Author: Okoro Chinedu
Market Jar Media Inc.
#170 – 422 Richards Street
Vancouver, BC, Canada
V6B 2Z4

comtex tracking


Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Daily Digitals News journalist was involved in the writing and production of this article.

You may also like...